 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- |||| TQL1055 adjuvant based acellular pertussis vaccine / Adjuvance Tech
Trial completion date, Trial termination: Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - Nov 1, 2022
P1, N=72, Terminated, Sponsor: Adjuvance Technologies, Inc.
Trial completion date: Sep 2022 --> Feb 2022 | Active, not recruiting --> Terminated; financial constraints
- || TQL1055 adjuvant based acellular pertussis vaccine / Adjuvance Tech
Enrollment closed, Trial completion date: Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - Aug 25, 2021
P1, N=60, Active, not recruiting, Sponsor: Adjuvance Technologies, Inc.
Trial completion date: Sep 2022 --> Feb 2022 | Active, not recruiting --> Terminated; financial constraints Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Sep 2022
- ||| TQL1055 adjuvant based acellular pertussis vaccine / Adjuvance Tech
Enrollment open: Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - Mar 18, 2021
P1, N=60, Recruiting, Sponsor: Adjuvance Technologies, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Sep 2022 Not yet recruiting --> Recruiting
- | TQL1055 adjuvant based acellular pertussis vaccine / Adjuvance Tech
New P1 trial: Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - Mar 10, 2021
P1, N=60, Not yet recruiting, Sponsor: Adjuvance Technologies, Inc.
- TQL1055 adjuvant based coronavirus vaccine / Adjuvance Tech, National Institute of Health and Medical Research
[VIRTUAL] The Novel Semisynthetic Saponin Adjuvant TQL1055 Enhances the Antibody Response to Pertussis Vaccine with an Improved Tolerability Profile over QS-21 () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_713;
Additionally, TQL1055 was better tolerated than QS-21, with no weight loss after vaccination. These findings suggested that TQL1055 may improve the performance of acellular pertussis vaccines without an increase in reactogenicity.
- TQL1055 adjuvant based coronavirus vaccine / Adjuvance Tech, National Institute of Health and Medical Research
[VIRTUAL] Robust Adjuvant Activity and Dose-sparing Potential of the Novel Semisynthetic Saponin Adjuvant TQL1055 for Seasonal and Pandemic Influenza. () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_696;
TQL1055 exhibits robust adjuvant activity for influenza antigens, demonstrating a dose-sparing effect and improved systemic tolerability compared with QS-21. Taken together, these finding support further evaluation of its potential as an adjuvant for influenza vaccines.